Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies

Inka Albrecht, Cecilia Wick, Asa Hallgren, Anna Tjärnlund, Kanneboyina Nagaraju, Felipe A Andrade, Kathryn Thompson, William Coley, Aditi Phadke, Lina Marcela Diaz-Gallo, Matteo Bottai, Inger Nennesmo, Karine Chemin, Jessica Herrath, Karin Johansson, Anders Wikberg, A. Jimmy Ytterberg, Roman A. Zubarev, Olof Danielsson, Olga Krystufkova & 6 others Jiri Vencovsky, Nils Landegren, Marie Wahren-Herlenius, Leonid Padyukov, Olle Kämpe, Ingrid E. Lundberg

Research output: Contribution to journalArticle

Abstract

Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

Original languageEnglish (US)
Pages (from-to)4612-4624
Number of pages13
JournalJournal of Clinical Investigation
Volume125
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Myositis
Autoantibodies
Muscular Diseases
Muscles
Autoimmunity
Granzymes
Muscular Atrophy
Muscle Proteins
Muscular Dystrophies
Muscle Weakness
Deglutition Disorders
Vasculitis
Autoimmune Diseases
Immunization
Peptide Hydrolases
Biomarkers
Mutation
Mortality
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Albrecht, I., Wick, C., Hallgren, A., Tjärnlund, A., Nagaraju, K., Andrade, F. A., ... Lundberg, I. E. (2015). Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies. Journal of Clinical Investigation, 125(12), 4612-4624. https://doi.org/10.1172/JCI81031

Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies. / Albrecht, Inka; Wick, Cecilia; Hallgren, Asa; Tjärnlund, Anna; Nagaraju, Kanneboyina; Andrade, Felipe A; Thompson, Kathryn; Coley, William; Phadke, Aditi; Diaz-Gallo, Lina Marcela; Bottai, Matteo; Nennesmo, Inger; Chemin, Karine; Herrath, Jessica; Johansson, Karin; Wikberg, Anders; Jimmy Ytterberg, A.; Zubarev, Roman A.; Danielsson, Olof; Krystufkova, Olga; Vencovsky, Jiri; Landegren, Nils; Wahren-Herlenius, Marie; Padyukov, Leonid; Kämpe, Olle; Lundberg, Ingrid E.

In: Journal of Clinical Investigation, Vol. 125, No. 12, 01.12.2015, p. 4612-4624.

Research output: Contribution to journalArticle

Albrecht, I, Wick, C, Hallgren, A, Tjärnlund, A, Nagaraju, K, Andrade, FA, Thompson, K, Coley, W, Phadke, A, Diaz-Gallo, LM, Bottai, M, Nennesmo, I, Chemin, K, Herrath, J, Johansson, K, Wikberg, A, Jimmy Ytterberg, A, Zubarev, RA, Danielsson, O, Krystufkova, O, Vencovsky, J, Landegren, N, Wahren-Herlenius, M, Padyukov, L, Kämpe, O & Lundberg, IE 2015, 'Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies', Journal of Clinical Investigation, vol. 125, no. 12, pp. 4612-4624. https://doi.org/10.1172/JCI81031
Albrecht, Inka ; Wick, Cecilia ; Hallgren, Asa ; Tjärnlund, Anna ; Nagaraju, Kanneboyina ; Andrade, Felipe A ; Thompson, Kathryn ; Coley, William ; Phadke, Aditi ; Diaz-Gallo, Lina Marcela ; Bottai, Matteo ; Nennesmo, Inger ; Chemin, Karine ; Herrath, Jessica ; Johansson, Karin ; Wikberg, Anders ; Jimmy Ytterberg, A. ; Zubarev, Roman A. ; Danielsson, Olof ; Krystufkova, Olga ; Vencovsky, Jiri ; Landegren, Nils ; Wahren-Herlenius, Marie ; Padyukov, Leonid ; Kämpe, Olle ; Lundberg, Ingrid E. / Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 12. pp. 4612-4624.
@article{9aee076d741649caa7547b43921b20a0,
title = "Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies",
abstract = "Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25{\%} of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.",
author = "Inka Albrecht and Cecilia Wick and Asa Hallgren and Anna Tj{\"a}rnlund and Kanneboyina Nagaraju and Andrade, {Felipe A} and Kathryn Thompson and William Coley and Aditi Phadke and Diaz-Gallo, {Lina Marcela} and Matteo Bottai and Inger Nennesmo and Karine Chemin and Jessica Herrath and Karin Johansson and Anders Wikberg and {Jimmy Ytterberg}, A. and Zubarev, {Roman A.} and Olof Danielsson and Olga Krystufkova and Jiri Vencovsky and Nils Landegren and Marie Wahren-Herlenius and Leonid Padyukov and Olle K{\"a}mpe and Lundberg, {Ingrid E.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1172/JCI81031",
language = "English (US)",
volume = "125",
pages = "4612--4624",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Development of autoantibodies against musclespecific FHL1 in severe inflammatory myopathies

AU - Albrecht, Inka

AU - Wick, Cecilia

AU - Hallgren, Asa

AU - Tjärnlund, Anna

AU - Nagaraju, Kanneboyina

AU - Andrade, Felipe A

AU - Thompson, Kathryn

AU - Coley, William

AU - Phadke, Aditi

AU - Diaz-Gallo, Lina Marcela

AU - Bottai, Matteo

AU - Nennesmo, Inger

AU - Chemin, Karine

AU - Herrath, Jessica

AU - Johansson, Karin

AU - Wikberg, Anders

AU - Jimmy Ytterberg, A.

AU - Zubarev, Roman A.

AU - Danielsson, Olof

AU - Krystufkova, Olga

AU - Vencovsky, Jiri

AU - Landegren, Nils

AU - Wahren-Herlenius, Marie

AU - Padyukov, Leonid

AU - Kämpe, Olle

AU - Lundberg, Ingrid E.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

AB - Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

UR - http://www.scopus.com/inward/record.url?scp=84948808386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948808386&partnerID=8YFLogxK

U2 - 10.1172/JCI81031

DO - 10.1172/JCI81031

M3 - Article

VL - 125

SP - 4612

EP - 4624

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -